Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

NCT02452866 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
325
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Symbiomix Therapeutics